France Pulls Getinge Vascular Grafts Over Yarn Defect

A field safety notice for two lines of Getinge implantable vascular grafts has surfaced in France, two weeks after the manufacturer first issued it. France's medicines and device regulator, ANSM, published a safety-information bulletin on 24 September describing a batch withdrawal of Intergard Synergy Knitted and Intergard Standard Knitted grafts — woven and knitted textile tubes used to replace or bypass diseased blood vessels — over loops of yarn found inside the graft's lumen, invisible from the outside of the device.

A lumen-side defect, invisible from outside

Vascular grafts in the Intergard family are knitted or woven polyester tubes, implanted to replace or bypass diseased sections of blood vessel; the Synergy and Standard Knitted variants are textile-construction devices meant to eventually integrate with surrounding tissue. The defect described in the field safety notice — loops of yarn inside the graft's lumen, the channel through which blood actually flows once implanted — is notable for being a manufacturing-line finding rather than a design or material problem, and one a surgeon could not identify by visual inspection of the device's exterior before implantation. Regulatory News could not independently confirm the specific clinical risk the notice attributes to the defect; a lumen-side irregularity in a blood-contacting implant is the kind of finding device-QA teams treat seriously regardless of whether an adverse event has been reported, and readers should treat any risk characterization beyond what is stated here as unconfirmed pending direct access to the full notice text.

How a field safety notice reaches the public

The sequence here is a normal one under the EU's field-safety-notice system, not evidence of a slow or hidden problem. A manufacturer identifying a defect issues a field safety notice directly to distributors, hospitals and national competent authorities; individual countries then publish their own public-facing safety communications on their own schedules. Intervascular's notice, dated 11 September, reached the public first through the Dutch inspectorate's website; France's ANSM followed on 24 September with its own bulletin, describing the same batch withdrawal in its own format. Regulatory News found no evidence these represent two separate incidents, and no evidence of how many EU member states beyond France and the Netherlands have published matching notices for the same field action — a typical MDR cascade can extend to every country where the affected batches were distributed, but only two national publications were independently confirmed here.

Frequently asked questions

What products are affected?

Intergard Synergy Knitted and Intergard Standard Knitted vascular prostheses made by Intervascular SAS, a Getinge subsidiary. Specific lot or batch numbers and a unit count were not confirmed in the portions of the notices available to Regulatory News.

What is the defect?

Small loops of yarn found inside the graft's lumen, not visible from the outside of the device. Neither notice, as found, spells out an explicit clinical-risk statement; readers should treat any specific risk description beyond that as unconfirmed.

Is this a coordinated EU-wide action?

At minimum, France and the Netherlands have published matching information tied to the same manufacturer field safety notice, dated 11 September 2026, with France's ANSM publishing its own bulletin on 24 September. Additional EU countries may have published matching notices; none were independently confirmed.

Is there a U.S. angle?

None was confirmed. No FDA recall notice tied specifically to the Intergard Synergy Knitted or Standard Knitted lines was identified, and no company statement beyond the field safety notice itself was found.